What is NDC 49702-231?

49702-231 is the product NDC for Triumeq, Abacavir sulfate 600 mg/1 + 2 more ingredients tablet, film coated, listed with the FDA by ViiV Healthcare Company. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Triumeq (Abacavir sulfate, dolutegravir sodium, lamivudine).

What is the active ingredient?

Abacavir sulfate, Dolutegravir sodium, Lamivudine.

ViiV Healthcare Company, NDC labeler code 49702. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Triumeq?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Triumeq NDC 49702-231 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)49702-231Labeler and product segments. Claims need a package NDC.

Product NDC at billing width49702-0231Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
49702-231-13	4970202311349702023113	30 TABLET, FILM COATED in 1 BOTTLE (49702-231-13)Marketed from Aug 22, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Triumeq
Generic name (nonproprietary): abacavir sulfate, dolutegravir sodium, lamivudine
Active ingredients: Abacavir sulfate — 600 mg/1Dolutegravir sodium — 50 mg/1Lamivudine — 300 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: ViiV Healthcare CompanyNDC labeler code 49702
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 205551
Marketing start: Aug 22, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 1A1 Inhibitors (Mechanism)HIV Integrase Inhibitors (Mechanism)Multidrug and Toxin Extrusion Transporter 1 Inhibitors (Mechanism)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)Organic Cation Transporter 2 Inhibitors (Mechanism)
Identifiers: Product ID 49702-231_4018a8c7-db0d-481e-b50a-a469ba32ec4bSPL ID 4018a8c7-db0d-481e-b50a-a469ba32ec4bSPL set ID 2997739a-aa91-42aa-a206-a70e2db7b84fRxCUI 1546888, 1546894, 2598348, 2598352UNII J220T4J9Q2, 1Q1V9V5WYQ, 2T8Q726O95UPC 0349702231139
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N449702023113 followed by a unit qualifier and the quantity

Package 49702-0231-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 8, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir). TRIUMEQ and TRIUMEQ PD are a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse tran…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 49702-231

What is NDC 49702-231?: 49702-231 is the product NDC for Triumeq, Abacavir sulfate 600 mg/1 + 2 more ingredients tablet, film coated, listed with the FDA by ViiV Healthcare Company. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Triumeq (Abacavir sulfate, dolutegravir sodium, lamivudine).
What is the active ingredient?: Abacavir sulfate, Dolutegravir sodium, Lamivudine.
Who is the labeler?: ViiV Healthcare Company, NDC labeler code 49702. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Triumeq?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.